MedTrace Logo

Early Detection of Alcoholic Liver Disease

NCT04070508 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-03-17

No results posted yet for this study

Summary

This is an observational study to identify the prevalence of advanced liver fibrosis among patients with excessive alcohol intake using a non-invasive method (FibroScan®) and to characterize the main environmental, genetic and epigenetic factors that could influence the development of advanced fibrosis.

The investigators will include patients 21 years of age or older with excessive alcohol intake, with abnormal AST, ALT, GGT and/or bilirubin, and without any evidence of decompensated liver disease (jaundice, ascites, encephalopathy).

Liver fibrosis will be estimated by FibroScan®. A designed questionnaire for studying environmental and psychosocial factors will be filled by the included patients, and blood samples will be obtained to study genetic and epigenetic factors.

The patients with advance fibrosis will be referred to the specialist for surveillance and treatment according to current clinical guidelines.

Conditions

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • RAMON BATALLER, MD, PhD · University of Pittsburgh

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2023-10-03
Completion
2025-11-03

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04070508 on ClinicalTrials.gov